Market closed · After hours · 4:13 PM ET
Last update: Nov 19, 2026, 3:32 PM ET
TG Therapeutics, Inc.
$64.85▼ 1.92% today
After Hours

Why TG Therapeutics, Inc. (TGTX) stock moved

Latest session▲ 5.4% · Nov 18, 2026 close

Why TG Therapeutics, Inc. (TGTX) rose 5.4% on November 18, 2026

TG Therapeutics, Inc. (TGTX) rose 5.4% on November 18, 2026, closing at $66.12 versus $62.71 the prior session (close-to-close, from daily closes). The move coincided with news that TGTX ranked #5 on Deloitte's 2026 Technology Fast 500 list of fastest-growing North American companies, and that Fifth Third Bancorp increased its TGTX stake by 181.1% to 171,291 shares in the latest quarter. Source: FMP price data; BestStocks detection.

Updated
Prior close
$62.71
Nov 18, 2026 close
$66.12
Change (close-to-close)
+$3.41
+5.44%
As first detected · Nov 18, 2026, 4:44 PM ET

TG Therapeutics, Inc. (TGTX) moved +5.56% from $62.64 to $66.12 on 2026-11-18, reaching a new 30-day high. The move coincided with news that TGTX ranked #5 on Deloitte's 2026 Technology Fast 500 list of fastest-growing North American companies, and that Fifth Third Bancorp increased its TGTX stake by 181.1% to 171,291 shares in the latest quarter.

What to watch next: TGTX earnings scheduled for 2026-02-25, with consensus EPS estimate of $0.56.

Source: FMP price data; BestStocks detection · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved TGTX

  1. −2.7%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst tied to the decline was found.
  2. +5.9%TG Therapeutics reported Q3 earnings today, beating both earnings and revenue estimates according to Zacks.
  3. +3.2%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  4. −5.9%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  5. +5.3%We checked news, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  6. +3.0%A Zacks report noted that TGTX is positioned to beat Q3 earnings estimates based on key fundamental strengths, with earnings scheduled to be announced on 2026-11-02 against a consensus EPS estimate of $0.37.
  7. −3.6%TGTX moved -4.04% from its $56.24 open to a $53.97 close on 2026-10-16.
  8. +3.8%The company scheduled multiple data presentations at the MSToronto2026 conference in October 2026.
  9. −3.2%A defenseworld.net analysis noted the stock had broken above its 200-day moving average, raising questions about momentum sustainability.
  10. −3.9%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  11. +2.7%TGTX moved +2.81% from its $55.95 open to a $57.52 close on 2026-09-24.
  12. −3.6%TGTX moved -3.63% from its $58.11 open to a $56.00 close on 2026-09-23.
  13. +5.3%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  14. −2.7%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  15. +3.3%The move was driven by unconfirmed takeover speculation from M&A blog Betaville suggesting potential interest from a larger biopharma suitor, combined with investor enthusiasm over the company's raised 2026 revenue guidance for its flagship multiple sclerosis drug Briumvi to approximately $950 million and H.C.

TG Therapeutics, Inc. (TGTX) shares fell 1.9% to $64.85 as of November 19, 2026, a modest decline from the prior close of $66.12. BestStocks flagged the session as a major change for TGTX. The move is tied to price move up. Below, we break down what changed for TGTX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

TGTX fell 1.9% to $64.85

TGTX fell 1.9% in its latest session, moving from $66.12 to $64.85.

Material / EarningsLow confidence
Rel. volume
0.8×
Below Avg
Vs peers
—
No comparable peers
Market cap
$9.8B
NASDAQ Capital Market
Analyst target
$81
+24.1% vs price
Price chart
Oct 19 – Nov 19
ENVVENN$53$60$66Oct 19Oct 27Nov 4Nov 11Nov 19
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for TG Therapeutics, Inc. investors

For TG Therapeutics, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Material negative event; Negative session, down 1.9%. Wall Street's consensus price target sits at $80.50, implying +24.1% upside from $64.85. BestStocks rates the overall signal quality low (41/100). With earnings roughly 98 days out, the next report is the most likely near-term test of the move.

TGTX price reaction

TGTX last traded at $64.85, down $1.27 (-1.92%) from the previous close of $66.12. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $53.16 and $66.12, and it currently sits about 90% of the way up that band.

Bullish and bearish analyst opinions on TG Therapeutics, Inc. (TGTX)

The consensus analyst price target on TG Therapeutics, Inc. (TGTX) is $80.50, 24.1% above the recent $64.85. Over the past 90 days analysts logged 0 upgrades, 2 maintains, and 0 downgrades. Here is how the bullish and bearish cases on TGTX line up.

The bullish case

  • Wall Street's consensus price target of $80.50 implies +24.1% upside from $64.85.
  • The Street's most bullish target is $83.00 (+28.0%).
  • Positive price momentum.

The bearish case

  • Material negative event.
  • Negative session, down 1.9%.
  • TG Therapeutics shares fell 2.17% to $52.74, reversing recent strength.
  • TG Therapeutics, Inc. (TGTX) moved -8.92% from $50.69 to $46.17 on 2026-08-03.
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $81+24.1%
= 2 maintains
Evercore ISI Group maintained Outperform · 2026-11-10
SEC filings watch
8-K2026-11-09
Material event — review for impact
high
10-Q2026-11-09
Quarterly financial results
medium
10-Q2026-08-05
Quarterly financial results
medium
8-K2026-08-03
Material event — review for impact
high
Peer context
TGTX-1.9%

Previous notable changes for TGTX

News2026-11-18+5.4%
TGTX ranked #5 on Deloitte's 2026 Technology Fast 500 list of fastest-growing North American companies.
Valuation2026-11-10+1.4%via defenseworld.net ↗
TG Therapeutics reported strong Q3 2026 results with total global revenue of $259.9 million (beating estimates) and raised full-year 2026 guidance to ~$1 billion from $950 million, driven by 14 consecutive quarters of sequential growth in its multiple sclerosis drug Briumvi (U.S. net revenue $232.6–$233 million). The stock gained 6.82% to $67.70 on the earnings announcement and an 8-K material event filing today.
Activity2026-11-09+5.9%via zacks.com ↗
TG Therapeutics reported Q3 earnings today, beating both earnings and revenue estimates according to Zacks. The stock rose 4.16% to $62.32 on elevated volume of 2.9M shares (2.08x the time-adjusted average), signaling investor approval of the results.
Material / Earnings2026-11-05-5.9%
TG Therapeutics, Inc. (TGTX) moved -5.72% from $61.50 to $57.98 on 2026-11-05. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume traded near its 5-day average, and the move occurred four days ahead of the company's scheduled earnings report on 2026-11-09.
Upcoming catalysts & outlook
Next earnings
2027-02-25 (est.)
in 98 days
Earnings Release
2027-02-25
High impact
Thesis shift
Bearish Shift
bearish signal
Risk level
High
from change events

Frequently asked questions about TGTX

Why did TG Therapeutics, Inc. (TGTX) stock move?

TG Therapeutics, Inc. (TGTX) rose 5.4% on November 18, 2026, closing at $66.12 versus $62.71 the prior session (close-to-close, from daily closes). The move coincided with news that TGTX ranked #5 on Deloitte's 2026 Technology Fast 500 list of fastest-growing North American companies, and that Fifth Third Bancorp increased its TGTX stake by 181.1% to 171,291 shares in the latest quarter. Source: FMP price data; BestStocks detection.

How much did TGTX stock fall?

TGTX lost 1.92% ($1.27) versus the prior close of $66.12, last trading at $64.85 on 0.8× average volume.

When is TG Therapeutics, Inc.'s next earnings date?

TGTX's next earnings report is estimated for 2027-02-25 — about 98 days away.

What is the analyst price target for TGTX?

The consensus analyst price target for TGTX is $80.50, about 24.1% above the current $64.85. Over the past 90 days, analysts recorded 0 upgrades, 2 maintains, and 0 downgrades.

How BestStocks tracks TGTX

This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for TGTX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataCompany news feedsSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.